Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan 9;55(1):1901407.
doi: 10.1183/13993003.01407-2019. Print 2020 Jan.

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

Affiliations
Free article
Editorial

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

Richard Beasley et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R. Beasley reports grants from Health Research Council of New Zealand, personal fees for consultancy from AstraZeneca, during the conduct of the study; grants and personal fees for advisory board work, consultancy and travel to meetings from AstraZeneca, grants from GlaxoSmithKline and Genentech, personal fees for advisory board work from Theravance Biopharma, outside the submitted work. Conflict of interest: I. Braithwaite reports grants from Health Research Council of New Zealand, during the conduct of the study; grants from Genentech, outside the submitted work. Conflict of interest: A. Semprini reports grants from Health Research Council of New Zealand, during the conduct of the study. Conflict of interest: C. Kearns has nothing to disclose. Conflict of interest: M. Weatherall has nothing to disclose. Conflict of interest: T.W. Harrison reports personal fees for consultancy from AstraZeneca, during the conduct of the study; personal fees for consultancy and lectures, and travel expenses reimbursement from AstraZeneca, personal fees for advisory board work from GSK, outside the submitted work. Conflict of interest: A. Papi reports personal fees for board membership, consultancy and lectures, grants for research, and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, personal fees for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon, personal fees for board membership and consultancy from Sanofi/Regeneron, outside the submitted work. Conflict of interest: I.D. Pavord reports personal fees for lectures and advisory board work, and travel expenses from AstraZeneca, GSK, Boehringer Ingelheim and TEVA, grants and personal fees for lectures and advisory board work, and travel expenses from Chiesi, personal fees for advisory board work from Sanofi/Regeneron, Merck, Novartis, Knopp and Roche/Genentech, personal fees for lectures from Circassia and Mundipharma, grants and personal fees for advisory board work from Afferent, outside the submitted work.

Comment in

Publication types